Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ZBTB16
REST API REST API
Homo sapiens
ZBTB16 is differentially expressed in 227 experiments: 117 organism parts: lung, skeletal muscle, ... (115 more);, 185 disease states: normal, lung adenocarcinoma, ... (183 more);, 77 cell types 145 cell lines 24 compound treatments and 65 other conditions.
Synonyms PLZF, ZNF145
Orthologs ZBTB16 (Gallus gallus)   Q32PJ4_BOVIN (Bos taurus)   Zbtb16 (Mus musculus)   Zbtb16 (Rattus norvegicus)   zbtb16 (Xenopus laevis)   XM_856200.1 (Canis familiaris)   ENSCAFG00000013538 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term transcriptional repressor complex, DNA binding, negative regulation of transcription, DNA-dependent, protein binding, nuclear speck, apoptosis, regulation of transcription, DNA-dependent, intracellular, negative regulation of cell proliferation, male germ-line stem cell division, metal ion binding, positive regulation of apoptosis, identical protein binding, hemopoiesis, leg morphogenesis, nucleus, nuclear body, protein homodimerization activity, positive regulation of transcription, DNA-dependent, central nervous system development, embryonic pattern specification, zinc ion binding, embryonic hindlimb morphogenesis, mesonephros development, positive regulation of chondrocyte differentiation, positive regulation of ossification, negative regulation of myeloid cell differentiation, forelimb morphogenesis, PML body, cartilage development, skeletal system development, positive regulation of cartilage development, embryonic limb morphogenesis, positive regulation of fat cell differentiation, myeloid cell differentiation, anterior/posterior pattern specification
InterPro Term Znf_C2H2-like, BTB_POZ, BTB/POZ-like, Znf_C2H2
Gene-Disease Assocation SKELETAL DEFECTS, GENITAL HYPOPLASIA, AND MENTAL RETARDATION
UniProt Accession Q05516, Q71UL6, Q71UL5, Q71UL7, F5H5Y7, F5H6C3
Search EB-eye ENSG00000109906
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-GEOD-3526, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-14464, E-GEOD-19639, E-GEOD-2450, E-GEOD-24147, ... (19 experiments)

Factor Value U/D Experiments
PC3
2
E-GEOD-14464, E-MEXP-2034
HL-60
2
E-MTAB-37, E-GEOD-24147
primary culture
2
E-GEOD-2450, E-GEOD-1657
HPAC
1
E-MTAB-37
NCIH1703
1
E-MTAB-37
DMS273
1
E-MTAB-37
139 more value(s).


Cell type

studied in E-GEOD-22529, E-TABM-40, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (38 experiments)

Factor Value U/D Experiments
normal
1
E-GEOD-6883
CD8+ naive CD8 T cell
1
E-TABM-40
plasmacytoid dendritic cell
1
E-TABM-34
platelet
1
E-GEOD-2006
alveolar space neutrophil
1
E-GEOD-2322
CD11c+ dendritic cell
1
E-MEXP-1600
71 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-TABM-15, E-MTAB-62, ... (61 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
1
3
E-GEOD-2514, E-MTAB-37, E-MEXP-231, E-MTAB-62
prostate carcinoma
1
3
E-MTAB-62, E-MTAB-37, E-MEXP-2034, E-GEOD-96
Duchenne muscular dystrophy
2
E-GEOD-3307, E-GEOD-1004
prostate adenocarcinoma
2
E-MTAB-62, E-GEOD-3868
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
oligodendroglioma with EGFR amplification
1
E-MEXP-1507
179 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-5824, E-GEOD-5099, E-MEXP-1337, E-GEOD-5339, ... (17 experiments)

Factor Value U/D Experiments
2-(3,4,5-trimethoxy-phenylamino)-pyrrolo[2,3-d]pyrimidines
1
E-GEOD-6932
hydrogen peroxide
1
E-GEOD-5339
dexamethasone/8-bromo cyclic AMP/isobutylmethylxanthine (DCI)
1
E-GEOD-3306
insulin
1
E-GEOD-22309
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
androgen + letrozole
1
E-GEOD-2225
18 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd38
studied in E-GEOD-22601

Chromosomal aberration
studied in E-GEOD-1729

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-GEOD-1140, ... (11 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1614, E-GEOD-1638, E-MEXP-2359, E-MEXP-958, E-MTAB-62 ... (5 experiments)

Disease staging
studied in E-GEOD-19743, E-GEOD-22544, E-GEOD-22148, E-TABM-147, E-GEOD-21138, ... (6 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011

Genotype
studied in E-TABM-763, E-GEOD-3494, E-GEOD-2466, E-GEOD-21750, E-TABM-321, ... (8 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-13073, E-GEOD-20504, E-MEXP-1446, E-GEOD-10315, E-GEOD-837, ... (7 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-740, E-GEOD-2466, E-MEXP-2069, ... (26 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-980

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-21750, E-GEOD-1657, E-MEXP-1403

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19246, E-GEOD-1343

RNAi
studied in E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2508, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

tissue (organ)
studied in E-GEOD-22601

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-21909, E-GEOD-19246, E-GEOD-19815 ... (5 experiments)

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-3494, E-GEOD-1561, E-GEOD-4922

Processing time: 0.545 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM